An N-terminally truncated envelope protein encoded by a human endogenous retrovirus W locus on chromosome Xq22.3
- Christina Roebke†1,
- Silke Wahl†1,
- Georg Laufer1,
- Christine Stadelmann2,
- Marlies Sauter1,
- Nikolaus Mueller-Lantzsch1,
- Jens Mayer3 and
- Klemens Ruprecht1, 4Email author
© Roebke et al; licensee BioMed Central Ltd. 2010
Received: 11 March 2010
Accepted: 24 August 2010
Published: 24 August 2010
We previously showed that the envelope (env) sequence of a human endogenous retrovirus (HERV)-W locus on chromosome Xq22.3 is transcribed in human peripheral blood mononuclear cells. The env open reading frame (ORF) of this locus is interrupted by a premature stop at codon 39, but otherwise harbors a long ORF for an N-terminally truncated 475 amino acid Env protein, starting at an in-frame ATG at codon 68. We set out to characterize the protein encoded by that ORF.
Transient expression of the 475 amino acid Xq22.3 HERV-W env ORF produced an N-terminally truncated HERV-W Env protein, as detected by the monoclonal anti-HERV-W Env antibodies 6A2B2 and 13H5A5. Remarkably, reversion of the stop at codon 39 in Xq22.3 HERV-W env reconstituted a full-length HERV-W Xq22.3 Env protein. Similar to the full-length HERV-W Env protein Syncytin-1, reconstituted full-length Xq22.3 HERV-W Env is glycosylated, forms oligomers, and is expressed at the cell surface. In contrast, Xq22.3 HERV-W Env is unglycosylated, does not form oligomers, and is located intracellularly, probably due to lack of a signal peptide. Finally, we reconfirm by immunohistochemistry that monoclonal antibody 6A2B2 detects an antigen expressed in placenta and multiple sclerosis brain lesions.
A partially defective HERV-W env gene located on chromosome Xq22.3, which we propose to designate ERVWE2, has retained coding capacity and can produce ex vivo an N-terminally truncated Env protein, named N-Trenv. Detection of an antigen by 6A2B2 in placenta and multiple sclerosis lesions opens the possibility that N-Trenv could be expressed in vivo. More generally, our findings are compatible with the idea that defective HERV elements may be capable of producing incomplete HERV proteins that, speculatively, may exert functions in human physiology or pathology.
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system affecting primarily young adults. While its precise aetiology is unknown, MS is thought to be a multifactorial disorder resulting from the interaction of environmental and genetic factors . A multiple sclerosis-associated retrovirus (MSRV) has previously been suggested by cDNA clones that were generated from particle-associated RNA from plasma or supernatants of cultured cells from patients with MS [2–4]. Subsequent investigations revealed MSRV-related sequences in the human genome, the human endogenous retrovirus family type W (HERV-W) .
HERVs are considered remnants of ancestral germ line infections by once active retroviruses and contribute approximately 8% of the human genome (for review see [6, 7]). Like their exogenous counterparts, HERVs typically consist of an internal region containing gag, pro, pol, and env genes, flanked by two long terminal repeats (LTR). The number and phylogenetic relationships among HERV-W sequences in the human genome have been addressed before [8, 9]. HERV-W is a multicopy endogenous retroviral family comprising approximately 650 elements. About 280 of those elements contain internal sequences . Individual HERV-W loci are defective due to the acquisition of stop-codons, truncations, and deletions. In addition, many HERV-W elements actually represent processed pseudogenes resulting from retrotransposition by long interspersed element (LINE) machinery [8, 9]. De Parseval et al. identified 13 HERV-W env elements in the human genome with full-length env genes . Among these, only one HERV-W env locus on chromosome 7q21.2, named ERVWE1, has retained an uninterrupted open reading frame (ORF) for a functional envelope (Env) protein, termed Syncytin-1, which is likely involved in placental morphogenesis [10, 11].
A number of previous reports have suggested a possible role of Syncytin-1 and/or MSRV Env protein in the pathogenesis of MS [4, 12–19]. MSRV/HERV-W env RNA is more abundant in autopsied brain tissue from patients with MS than from controls [12, 16, 17, 19]. A monoclonal anti-HERV-W Env antibody (mAb 6A2B2) detects an antigen expressed in actively demyelinating brain lesions from patients with MS [12, 16, 18]. Importantly, expression of Syncytin-1 in astrocytes induces release of mediators that are cytotoxic to oligodendrocytes (the cells responsible for myelination) in vitro, and the expression of Syncytin-1 in murine models causes oligodendrocyte loss and demyelination in vivo [16, 18]. On the other hand, MSRV Env protein (AAK18189.1) has been suggested to have superantigen-like properties , and the surface (SU) domain of MSRV Env, which is 87% identical to Syncytin-1, was reported to have proinflammatory effects via activation of CD14 and toll-like receptor 4 .
Despite the potential involvement of Syncytin-1 and MSRV Env in MS, the precise origin of MSRV env sequences and their relation to endogenous HERV-W env loci has not been clear [19–23]. We recently proposed that formerly reported MSRV env sequences may be explained as being derived from transcripts of various genomic HERV-W env loci or from recombinations among those transcripts . By analogy to data obtained from a study of transcribed HERV-W env loci in human peripheral blood mononuclear cells (PBMC), and from a study of transcribed HERV-K(HML-2) loci, it seems possible that those recombinations occurred in vitro because of template switches of reverse transcriptase during cDNA generation and/or via PCR-mediated recombinations [24, 25].
In particular, our analyses showed that the SU region and the 5' part of the transmembrane (TM) region of the reported MSRV env sequence AF331500 are highly similar to a HERV-W env locus on human chromosome Xq22.3, while the 3' part of the TM region of AF331500 is highly similar to a HERV-W element on chromosome 5p12. Another published MSRV env sequence (AF127228) was found to be almost identical with the HERV-W locus on chromosome Xq22.3 as well . The Xq22.3 HERV-W env locus is quite remarkable as it harbors an almost complete ORF for a full-length HERV-W Env protein, only interrupted by a single premature stop at codon 39. The longest possible ORF of HERV-W Xq22.3 env, starting at an in-frame ATG at codon 68, could produce an N-terminally truncated HERV-W Env protein of 475 amino acids. Others and we previously showed that Xq22.3 HERV-W env is transcribed in human PBMC [24, 26, 27]. Similar to other transcribed HERV-W elements, the Xq22.3 locus lacks a 5'LTR promotor, suggesting that another upstream promotor drives its transcription [26, 27]. While that promotor remains to be identified, Xq22.3 HERV-W env transcripts indicate that the locus fulfills one essential prerequisite for protein production.
Intriguingly, it turned out that anti-HERV-W Env mAb 6A2B2 (detecting an antigen in MS brain lesions, see above) was raised against a 379 amino acid sequence encoded by MSRV env clone AF127228, which, except for two C-terminal amino acid exchanges, is identical to the Xq22.3 HERV-W Env amino acid sequence [11, 24]. Although 6A2B2 may crossreact with Syncytin-1 [11, 28, 29], these findings open up the possibility that the protein detected by 6A2B2 in MS lesions may in fact be derived from Xq22.3 HERV-W env. Nonetheless, it was unknown whether a protein encoded by Xq22.3 HERV-W env can be expressed in human cells.
We herein show that Xq22.3 HERV-W env is capable of producing an N-terminally truncated HERV-W Env protein ex vivo. Reversion of the stop codon at position 39 in Xq22.3 HERV-W env results in the expression of a reconstituted full-length HERV-W Env protein. We characterize properties of truncated and reconstituted Xq22.3 HERV-W Env in comparison to Syncytin-1 and MSRV Env. We also confirm that mAb 6A2B2 detects an antigen expressed in placenta and MS brain lesions. Our data support the idea that not only HERVs with ORFs for complete retroviral proteins but also defective HERV elements may be capable of producing pieces of HERV proteins, which, speculatively, may exert functions in human physiology or pathology.
Expression of an N-terminally truncated Env protein from HERV-W Xq22.3
To analyze the coding capacity of Xq22.3 HERV-W env, we PCR-amplified from human genomic DNA a 1862 bp sequence beginning at the ATG at codon 68 of Xq22.3 HERV-W env and containing the putative 475 amino acid HERV-W env ORF as well as the 3'LTR portions (Figure 1A). The amplicon was cloned into phCMV, a eukaryotic expression vector under the control of a strong hCMV promotor, generating phCMV-Xq22.3 Env. Another expression plasmid (phCMV-Xq22.3 Env FL) harboring an 2134 bp insert comprising the full-length Xq22.3 HERV-W env sequence was created similarly (Figure 1A).
Reconstitution of full-length Xq22.3 HERV-W Env
We generated an expression plasmid (phCMV-Xq22.3 Env FLΔStop) with an uninterrupted ORF for a full-length 542 amino acid Xq22.3 HERV-W Env protein by reversing the stop codon (TGA) at position 39 of Xq22.3 HERV-W env into a tryptophan residue (TGG) (Figure 1A). For comparative analysis with phCMV-Xq22.3 Env FLΔStop we included plasmid phCMV-MSRV Env (pV14), containing the AF331500 MSRV env sequence. The structure and possible origin of the AF331500 MSRV env sequence were previously discussed in detail . Finally, since Synyctin-1 currently represents the only known functional and thoroughly characterized HERV-W Env protein , we also employed the phCMV-Syncytin-1 (PH74) expression vector in this investigation.
Remarkably, reversion of the stop codon in Xq22.3 HERV-W env resulted in the expresssion of a ~75 kDa Xq22.3 HERV-W Env protein, as detected by mAb 13H5A5 (Figure 2A, top panel). This antibody also confirmed expression of MSRV Env, with both Xq22.3 Env FLΔStop and MSRV Env proteins having similar molecular weights. Of note, mAb 13H5A5 did not detect Syncytin-1. However, a polyclonal rabbit antibody (pAb) against Syncytin-1 readily recognized Syncytin-1 (Figure 2A, bottom panel). The anti-Syncytin-1 pAb, which is directed against the N-terminus of Syncytin-1, did not cross-react with Xq22.3 Env, further corroborating that Xq22.3 Env is an N-terminally truncated protein. The observed molecular weight of Syncytin-1 is compatible with results from Cheynet et al.  who reported the full-length Syncytin-1 precursor to be synthesized as a glycosylated 73 kDa protein. It follows that the proteins of approximately similar weight seen for Xq22.3 Env FLΔStop and MSRV Env represent complete HERV-W Env precursor proteins as well. Altogether, reversion of the N-terminal stop codon in Xq22.3 env results in the expression of a "resurrected", untruncated, full-length Xq22.3 HERV-W Env precursor protein.
Specificities of different anti-HERV-W Env antibodies for HERV-W Env constructs
In addition to mAb 13H5A5 and the anti-Syncytin-1 pAb, we also studied the specificity for HERV-W Env proteins of a pAb directed against the 80 C-terminal amino acids of Xq22.3 HERV-W Env. This pAb was generated with the aim of producing a polyclonal rabbit serum that specifically targets Xq22.3 Env. The C-terminal region of Xq22.3 Env was chosen as it displays a number of residues different from MSRV Env and Syncytin-1 (Figure 1B). Indeed, the anti-Xq22.3 Env pAb detected Xq22.3 Env and Xq22.3 Env FLΔStop, but only very weakly MSRV Env (Figure 2A, second panel from bottom). However, it cross-reacted with Syncytin-1, which precluded its use as a tool for exclusive detection of Xq22.3 Env.
We also investigated specificity of mAb 6A2B2 for proteins produced by the different HERV-W Env expression vectors. In our hands, 6A2B2 did detect Xq22.3 Env, Xq22.3 Env FLΔStop, and MSRV Env, but not Syncytin-1 (Figure 2A, second panel from top). A band of ~43 kDa was additionally observed in blots developed with 6A2B2, and infrequently also in blots developed with 13H5A5. This ~43 kDa band was judged unspecific as it was also detected in lysates from a cell line (B95.8) derived from a new world monkey that lacks HERV-W  (data not shown).
To summarize the specificities, as established by immunoblot and immunocytochemistry, of all antibodies employed in this work, mAbs 13H5A5 and 6A2B2 detected Xq22.3 Env, Xq22.3 Env FLΔStop, and MSRV Env, but not Syncytin-1. The Xq22.3 Env pAb recognized Xq22.3 Env, Xq22.3 Env FLΔStop, and Syncytin-1, but only very weakly MSRV Env. Finally, the anti-Syncytin-1 pAb reacted with Syncytin-1, Xq22.3 Env FLΔStop, and MSRV Env, but not with Xq22.3 Env.
Xq22.3 Env is unglycosylated, does not form oligomers, and is not located to the cell surface
To analyze the capacity of the various HERV-W Env proteins to form oligomers, immunoblots were carried out under reducing and non-reducing conditions. Non-reducing conditions resulted in several high molecular weight bands for Syncytin-1, Xq22.3 Env FLΔStop, and MSRV Env, but no such oligomeric complexes could be observed for Xq22.3 Env (Figure 4B). While the exact composition of those higher molecular weight complexes remains to be determined, our results indicate that Syncytin-1, Xq22.3 Env FLΔStop, and MSRV Env can oligomerize, whereas Xq22.3 Env cannot.
Surface expression of MSRV Env, Xq22.3 Env FLΔStop, and Xq22.3 Env was studied by immunocytochemistry of living, unfixed, and unpermeabilized HeLa cells transfected with respective constructs. Intracellular expression was analyzed in parallel in fixed and permeabilized cells. Whereas MSRV Env and Xq22.3 Env FLΔStop were clearly detectable at the cell surface and in the cytoplasm, Xq22.3 Env was only located in the cytoplasm, suggesting that Xq22.3 Env is not transported to the plasma membrane (Figure 4C). The results obtained by immuncytochemistry were confirmed by flow cytometry experiments in which surface expression was likewise only detectable for MSRV Env and Xq22.3 Env FLΔStop, but not for Xq22.3 Env (Figure 4D).
A single amino acid mutation inhibits cleavage of HERV-W Env Xq22.3 into SU and TM subunits
MSRV Env, Xq22.3 Env FLΔStop, and Xq22.3 Env do not induce syncytia in HeLa cells
RNA transcripts from the Xq22.3 HERV-W envlocus have the correct orientation for translation of a Xq22.3 HERV-W Env protein
Monoclonal antibody 6A2B2 detects an antigen expressed in placenta and acute MS lesions
We herein show that a processed HERV-W pseudogene which is located on chromosome Xq22.3 and discloses an N-terminally truncated 475 amino acid long env ORF can produce an N-terminally truncated HERV-W Env protein ex vivo. We named this protein N-Trenv (for N-terminally truncated Env). By analogy to the ERVWE1 gene encoding Syncytin-1, we propose to designate the Xq22.3 HERV-W env gene that encodes N-Trenv ERVWE2. While the ERVWE1 gene has been the only HERV-W env locus shown to be capable of producing a protein so far, our results establish Xq22.3 HERV-W env (ERVWE2) as the second HERV-W env element in the human genome that has retained coding capacity.
Viral membrane glycoproteins, such as retroviral Env proteins, are normally synthesized in the endoplasmic reticulum . Targeting of nascent polypeptide chains of retroviral Env proteins to the endoplasmic reticulum membrane is brought about by a short stretch of amino acids at the N-terminus of the protein, the so-called signal peptide . Due to its N-terminal truncation N-Trenv lacks a signal peptide and is therefore very likely synthesized on free ribosomes. Consequently, N-Trenv is not expected to undergo the usual maturation steps of full-length retroviral Env proteins. Indeed, N-Trenv is an unglycosylated protein, that does not form oligomers and is not transported to the cell surface. While functional properties of N-Trenv are currently unknown, those features suggest that in terms of function N-Trenv may behave quite differently from full-length retroviral Env proteins. Remarkably, reversion of the premature stop at codon 39 in ERVWE2 "resurrected" full-length Xq22.3 HERV-W Env protein which then became glycosylated, formed oligomers, and was expressed at the cell surface, just like the full-length HERV-W Env protein Syncytin-1 . A single nucleotide difference in ERVWE2 can therefore dramatically alter properties of the ERVWE2 gene product. Nevertheless, unlike Syncytin-1, reconstituted Xq22.3 HERV-W Env does not appear to be cleaved into SU and TM domains, due to an amino acid mutation in the furin cleavage motif. As cleavage is prerequisite for proper Env function, it is doubtful whether reconstituted Xq22.3 HERV-W Env could represent a fully functional retroviral Env protein that confers infectivity on retrovirus particles, as it was shown for Syncytin-1 .
Given the fundamental changes in the properties of N-Trenv resulting from elimination of the premature stop codon in ERVWE2, one may speculate whether a suppression of this stop codon could occur in human beings in vivo leading to re-expression of full-length Env with possible functional consequences. Furthermore, it would be interesting to know whether there exist ERVWE2 alleles in the human population that lack the stop codon. An approach to test this hypothesis would be a genetic one, with a screening for mutations in the ERVWE2 stop codon in the general population, or at a more refined level, in certain patient groups, e.g. individuals suffering from MS.
Others and we have previously shown expression of Xq22.3 HERV-W env transcripts in human PBMC [24, 26, 27]. Using strand-specific reverse transcription, we here confirm that Xq22.3 HERV-W env is transcribed in the correct orientation for subsequent translation into a protein. The overall structure of Xq22.3 HERV-W env transcripts, such as location of upstream transcription initiator(s), downstream polyadenylation signals, and potential splicing of transcripts, must be addressed in separate studies.
An obviously important question is whether N-Trenv may be expressed in the human organism in vivo. As our analysis showed, mAb 13H5A5 appears to specifically detect N-Trenv, but not Syncytin-1, and could thus be suited for immunohistochemical studies addressing in vivo expression of N-Trenv. Indeed, in a previous immunohistochemical study mAb 13H5A5 was shown to detect an antigen expressed in microglia, lymphocytes, and endothelial cells in formalin-fixed, paraffin-embedded normal human brain tissue and inflammatory MS brain lesions, which were pretreated for antigen retrieval . These data point towards the possibility that N-Trenv could be expressed in normal and diseased human brain in vivo. Nevertheless, providing definitive proof that the protein product of a specific HERV locus is expressed in vivo is not a simple task. For instance, it cannot be excluded that besides ERVWE2 further defective HERV-W env loci in the human genome may have the capacity to express incomplete HERV-W Env proteins that might accidentally contain the epitope recognized by mAb 13H5A5. If this was the case, it would be quite challenging to dissect from which specific HERV-W env locus the observed proteins precisely originate. Our present and previously reported findings do therefore not provide formal prove that N-Trenv is expressed in vivo, underscoring the complexity of investigations on HERV protein expression in vivo.
Since mAb 6A2B2 was raised against a 379 amino acid fragment that is identical to the N-Trenv amino acid sequence except for two C-terminal amino acid exchanges , detection of N-Trenv, reconstituted full-length Xq22.3 Env, and MSRV Env by 6A2B2 was expected. However, in our hands 6A2B2 did not recognize Syncytin-1. This was an unanticipated finding as 6A2B2 has previously been reported to detect Syncytin-1 [11, 28, 29]. A possible explanation for this discrepancy could be that 6A2B2 recognizes an epitope that is conformational or only exhibited by oligomerized forms of Syncytin-1 and that was lost under the experimental conditions applied in our study. Consistent with this idea, in a previous work which reported detection of Syncytin-1 by 6A2B2 in an immunoblot, the respective experiment was carried out under non-reducing conditions . Also consistent with this idea, mAb 6A2B2 was previously shown to react with transiently expressed Syncytin-1 in flow cytometry experiments, where conformational epitopes should be detectable .
However, in double immunofluorescence experiments of placental tissue with mAb 6A2B2 and anti-Syncytin-1 pAb both antibodies revealed different staining patterns. Staining with anti-Syncytin-1 pAb was most prominent at the syncytiotrophoblast membrane. Consistent with the detection of Syncytin-1 by the anti-Syncytin-1 pAb in immunoblots and immunocytochemistry, and Syncytin-1 being a membrane-associated protein, this finding is compatible with the detection of Syncytin-1 at the syncytiotrophoblast membrane by the anti-Syncytin-1 pAb. In contrast, membrane-associated immunoreactivity was not observed with mAb 6A2B2 which revealed a more diffuse cytoplasmic staining of the syncytiotrophblast cell layer as well as of cells within the placental mesenchyme. Altogether, these data suggest that, in keeping with our findings on the specificity of mAb 6A2B2 for HERV-W Env proteins in immunoblots and immuncytochemistry, mAb 6A2B2 might also recognize an antigen that is different from Syncytin-1 in immunohistochemistry. It follows that the immunoreactivity observed in MS lesions stained with mAb 6A2B2 in former studies [12, 16, 18] and this work may indicate expression of an HERV-W Env antigen different from Syncytin-1 in MS brain lesions. Similar to what has been discussed above for mAB 13H5A5, while the precise identity of the antigen recognized by mAb 6A2B2 in placental tissue and MS brain lesions remains to be clarified, N-Trenv is one possibility.
Finally, it is well established that some HERV loci in the human genome have the capacity to produce proteins that can be expressed under physiological but also pathological conditions [7, 34]. Research in this field has primarily focused on those few HERV elements that harbor intact ORFs coding for complete retroviral proteins . Nevertheless, there may be instances in which short proteins also produced by highly defective HERV loci may exert a biologically significant function . Our present findings further strengthen the idea that incomplete or truncated HERV loci also may be capable of producing pieces of proteins.
In summary, we show that a partially defective HERV-W env gene on chromosome Xq22.3, that we propose to name ERVWE2, can produce ex vivo an N-terminally truncated HERV-W Env protein, named N-Trenv, and has thus retained a coding capacity. Our own and previously published data are compatible with the possibility that N-Trenv could also be expressed in vivo, although formal proof is still required. While most of the numerous HERV elements in the human genome are defective and have therefore been considered functionless, our present findings suggest that defective HERV elements in the human genome may be capable of also producing partial HERV proteins. It is tempting to speculate that those HERV protein fragments could play a role in human physiology or pathology.
Nucleotides 106,181,958-106,184,091 from chromosome × (human genome March 2006 assembly), containing the complete Xq22.3 HERV-W env sequence, 71 bp of the 3' end of the pol gene, as well as 3' LTR portions were PCR-amplified from human genomic DNA. All primer sequences are available from the authors upon request. The PCR product was cloned in either sense or antisense orientation (as control) into the BamHI site of phCMV, generating phCMV-Xq22.3 Env FL (full-length). To create an expression vector containing a complete Xq22.3 HERV-W env ORF (phCMV-Xq22.3 Env FLΔStop), the stop codon (TGA) at codon 39 of the Xq22.3 HERV-W env sequence present in phCMV-Xq22.3 Env FL was reverted to tryptophan (TGG) by employing a PCR-mediated approach. Expression plasmid phCMV-Xq22.3 Env, starting at the first in-frame ATG (codon 68) downstream from the stop at codon 39 in Xq22.3 HERV-W env and containing the 475 amino acid ORF of Xq22.3 HERV-W env and the adjacent 3'LTR sequence was generated by PCR-amplification of nucleotides 106,181,958-106,183,819 of chromosome × from human genomic DNA. The amplicon was introduced in either sense or antisense orientation into the BamHI site of phCMV. Sequencing of phCMV-Xq22.3 Env and phCMV-Xq22.3 Env FL (GATC Biotech, Konstanz, Germany) confirmed identity with the Xq22.3 human genome sequence (March 2006 assembly) and reversion of the stop codon in phCMV-Xq22.3 Env FLΔStop (data not shown). Plasmids phCMV-Syncytin-1 (clone PH74, AF 072506) , and phCMV-MSRV Env (clone pV14, AF 331500)  were kindly provided by Hervé Perron (Geneuro, Switzerland). As an additional control, we also inserted the MSRV env sequence in antisense orientation into phCMV.
Polyclonal anti-Syncytin-1 rabbit antisera (anti-Syncytin-1 pAb K342 and K343) were generated as previously described [36, 37] by immunization of rabbits with a fusion protein consisting of an approximately 6 kDa fragment of the N-terminus of Syncytin-1 and E. coli anthranilate synthetase (TrpE). A polyclonal anti-Xq22.3 HERV-W Env antiserum (anti-Xq22.3 Env pAb) was produced similarly by immunizing rabbits with a fusion protein consisting of the 80 C-terminal amino acids (463-542) of Xq22.3 HERV-W Env fused to TrpE (see also Figure 1A). In competition experiments, the anti-Xq22.3 HERV-W Env antiserum was preadsorbed overnight with either bacterially expressed TrpE-Xq22.3 HERV-W Env fusion protein or TrpE alone. The mouse mAb 13H5A5 (IgG1κ), directed against an epitope in the SU domain of MSRV Env , and peroxidase labeled mouse mAb 6A2B2 (IgG1κ) were a kind gift from Hervé Perron. As previously discussed in detail, mAb 6A2B2 was raised against a 379 amino acid sequence encoded by MSRV env clone AF127228, which is identical to the Xq22.3 HERV-W Env amino acid sequence but for two C-terminal amino acid exchanges [11, 24].
Transient expression and characterization of HERV-W Env proteins
HeLa human cervical carcinoma cells were cultured in Dulbecco's modified Eagle's medium containing 10% FCS (PAA), penicillin (100 U/ml), and streptomycin (100 μg/ml). Cells were maintained at 37° C in a 5% CO2 atmosphere. Cells were free of mycoplasma contamination, as confirmed by PCR (Venor GeM, Minerva Biolabs). For transient expression of HERV-W Env proteins, HeLa cells were plated into 6-well plates (5 × 105 cells/well) and transfected the following day with different HERV-W Env expression plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After approximately 48 hours, cells were lysed in sample buffer (125 mM Tris-HCl [pH 6.8], 6% [w/v] sodium dodecyl sulfate [SDS], 10% [v/v] mercaptoproprandiol, 10% [v/v] glycerol), sonicated, and boiled for 5 minutes. To assay for HERV-W Env oligomers, mercaptoproprandiol was omitted from the sample buffer and lysates were not boiled. For immunoblot analyses, 15 μg of protein were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore). Membranes were probed with primary antibodies as indicated and developed with secondary peroxidase labeled IgG antibodies (Sigma) and enhanced chemoluminescence. To analyze glycosylation of HERV-W Env proteins, 30 μg of protein were denatured at 100°C for 10 minutes and digested with 500 Units PNGase F (New England BioLabs) for 4 hours at 37°C according to the manufacturer's instructions.
HeLa cells transfected with the different HERV-W Env expression vectors were washed with PBS and detached with 0.02% Versene in PBS. Cells were incubated with primary antibody 13H5A5, diluted in FACS buffer (PBS, 2% [v/v] FCS), for 1 hour at 4°C, washed with FACS buffer, and incubated with a fluorescein isothiocyanate-conjugated anti-Mouse IgG secondary antibody (Sigma). Cells were washed, resuspended in isotonic NaCl 1% (v/v) paraformaldehyde (PFA) [pH 7,4], and 104 cells/sample were analyzed using a Beckton Dickinson FACScan.
For immunocytochemistry, HeLa cells were plated at 3 × 104 cells per well (growth area 0.9 cm2 per well) on microscope slides using flexible 8-well tissue culture chambers attached onto the slides (flexiPerm, Greiner Bio-one). The following day, cells were transfected using Lipofectamine and medium was replaced 4 hours after transfection. For whole cell staining, cells were washed one day later with PBS, fixed with 4% (v/v) PFA in PBS, permeabilized with 0.2% (v/v) Triton-X 100 in PBS, blocked with 10% (v/v) FCS in PBS, and stained with antibodies diluted in PBS/10% FCS. Following incubation with secondary antibody (goat-anti-rabbit IgG Alexa Fluor 568, 1:1000, Molecular Probes), cells were dehydrated in 70%, 80%, and 100% ethanol and mounted with Vectashield (Vector) medium containing 4',6'-diamidino-2-phenylindole (DAPI). For surface staining, living, unfixed, and unpermeabilized cells were stained on ice with primary antibodies as indicated. After incubation with secondary antibody, cells were fixed with PFA. Slides were inspected with a Leitz Aristoplan fluorescence microscope and images were acquired using AxioVision 3.0 software. Digital acquisition parameters and further processing (Corel Photo-Paint 12) were identical for all images.
Formation of syncytia
HeLa cells were plated at 5 × 105 cells/per well in 6-well plates and transfected (Lipofectamine 2000) with different HERV-W Env constructs. After 24 hours cells were stained with May-Grünwald and Giemsa solutions to visualize syncytia formation and inspected with a Leitz Aristoplan microscope.
Immunohistochemistry was carried out as previously described  on formalin-fixed paraffin-embedded post-mortem brain tissue sections from a 76-year old woman with fulminant MS (Marburg's variant) as well as on formalin-fixed paraffin-embedded tissue sections from normal human placenta. For double immunofluorescence Cy2-conjugated anti-mouse-IgG and Cy3-conjugated anti-rabbit IgG (Dianova, Hamburg, Germany) were used as secondary antibodies.
Strand specific RT-PCR
Total RNA was prepared from PBMC using the RNeasy Mini kit (Qiagen) and eluted into 60 μl of RNase-free H2Odd. RNA concentration and purity was assessed spectrophotometrically. Contaminating DNA was removed using the TURBO DNA-free Kit (Ambion Inc.) following the protocol for rigorous DNAse treatment as described before . Reverse transcription was carried out using the Xq22.3 HERV-W env strand-specific primers Sense 5'-GCTGCTGTACAACCAGTAGCTC-3' and Antisense 5'-TTCTCTTGCCTGACCTTGAAT-3' and SuperScript III reagents (Invitrogen) at 55°C for increased specificity. Negative controls were generated in parallel for each sample by omitting reverse transcriptase from the reaction. PCR was carried out as reported  using above mentioned primers. For further verification PCR products were cloned and sequenced as described before .
The authors would like to thank Hervé Perron, Geneuro, Switzerland, for providing 13H5A5 and 6A2B2 antibodies as well as MSRV env pV14 and Syncytin-1 pH74 plasmids. We also thank Alessia Ruggieri for helpful discussions. This study was supported by grants from HOMFOR and DFG.
- Noseworthy JH: Progress in determining the causes and treatment of multiple sclerosis. Nature. 1999, 399: A40-A47.View ArticlePubMedGoogle Scholar
- Komurian-Pradel F, Paranhos-Baccala G, Bedin F, Ounanian-Paraz A, Sodoyer M, Ott C, Rajoharison A, Garcia E, Mallet F, Mandrand B, Perron H: Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles. Virology. 1999, 260: 1-9. 10.1006/viro.1999.9792.View ArticlePubMedGoogle Scholar
- Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, Mallet F, Tuke PW, Voisset C, Blond JL, Lalande B, Seigneurin JM, Mandrand B: Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci USA. 1997, 94: 7583-7588. 10.1073/pnas.94.14.7583.PubMed CentralView ArticlePubMedGoogle Scholar
- Perron H, Jouvin-Marche E, Michel M, Ounanian-Paraz A, Camelo S, Dumon A, Jolivet-Reynaud C, Marcel F, Souillet Y, Borel E, Gebuhrer L, Santoro L, Marcel S, Seigneurin JM, Marche PN, Lafon M: Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology. 2001, 287 (2): 321-332. 10.1006/viro.2001.1045.View ArticlePubMedGoogle Scholar
- Blond J-L, Beseme F, Duret L, Bouton O, Bedin F, Perron H, Mandrand B, Mallet F: Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol. 1999, 73: 1175-1185.PubMed CentralPubMedGoogle Scholar
- Bannert N, Kurth R: Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci USA. 2004, 101 (Suppl 2): 14572-14579. 10.1073/pnas.0404838101.PubMed CentralView ArticlePubMedGoogle Scholar
- de Parseval N, Heidmann T: Human endogenous retroviruses: from infectious elements to human genes. Cytogenet Genome Res. 2005, 110: 318-332. 10.1159/000084964.View ArticlePubMedGoogle Scholar
- Pavlicek A, Paces J, Elleder D, Hejnar J: Processed pseudogenes of human endogenous retroviruses generated by LINEs: their integration, stability, and distribution. Genome Res. 2002, 12: 391-399.PubMed CentralView ArticlePubMedGoogle Scholar
- Costas J: Characterization of the intragenomic spread of the human endogenous retrovirus family HERV-W. Mol Biol Evol. 2002, 19 (4): 526-533.View ArticlePubMedGoogle Scholar
- de Parseval N, Lazar V, Casella JF, Benit L, Heidmann T: Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol. 2003, 77 (19): 10414-10422. 10.1128/JVI.77.19.10414-10422.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Blond JL, Lavillette D, Cheynet V, Bouton O, Oriol G, Chapel-Fernandes S, Mandrand B, Mallet F, Cosset FL: An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor. J Virol. 2000, 74: 3321-3329. 10.1128/JVI.74.7.3321-3329.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Mameli G, Astone V, Arru G, Marconi S, Lovato L, Serra C, Sotgiu S, Bonetti B, Dolei A: Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not human herpesvirus 6. J Gen Virol. 2007, 88: 264-274. 10.1099/vir.0.81890-0.View ArticlePubMedGoogle Scholar
- Perron H, Lazarini F, Ruprecht K, Pechoux-Longin C, Seilhean D, Sazdovitch V, Creange A, Battail-Poirot N, Sibai G, Santoro L, Jolivet M, Darlix JL, Rieckmann P, Arzberger T, Hauw JJ, Lassmann H: Human endogenous retrovirus (HERV)-W env and gag proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol. 2005, 11: 23-33. 10.1080/13550280590901741.View ArticlePubMedGoogle Scholar
- Rolland A, Jouvin-Marche E, Saresella M, Ferrante P, Cavaretta R, Creange A, Marche P, Perron H: Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated RetroViral element) envelope protein in patients with multiple sclerosis. J Neuroimmunol. 2005, 160 (1-2): 195-203. 10.1016/j.jneuroim.2004.10.019.View ArticlePubMedGoogle Scholar
- Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN: The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol. 2006, 176 (12): 7636-7644.View ArticlePubMedGoogle Scholar
- Antony JM, van Marle G, Opii W, Butterfield DA, Mallet F, Yong VW, Wallace JL, Deacon RM, Warren K, Power C: Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci. 2004, 7 (10): 1088-1095. 10.1038/nn1319.View ArticlePubMedGoogle Scholar
- Antony JM, Izad M, Bar-Or A, Warren KG, Vodjgani M, Mallet F, Power C: Quantitative analysis of human endogenous retrovirus-W env in neuroinflammatory diseases. AIDS Res Hum Retroviruses. 2006, 22 (12): 1253-1259. 10.1089/aid.2006.22.1253.View ArticlePubMedGoogle Scholar
- Antony JM, Ellestad KK, Hammond R, Imaizumi K, Mallet F, Warren KG, Power C: The human endogenous retrovirus envelope glycoprotein, syncytin-1, regulates neuroinflammation and its receptor expression in multiple sclerosis: a role for endoplasmic reticulum chaperones in astrocytes. J Immunol. 2007, 179 (2): 1210-1224.View ArticlePubMedGoogle Scholar
- Antony JM, Zhu Y, Izad M, Warren KG, Vodjgani M, Mallet F, Power C: Comparative expression of human endogenous retrovirus-W genes in multiple sclerosis. AIDS Res Hum Retroviruses. 2007, 23 (10): 1251-1256. 10.1089/aid.2006.0274.View ArticlePubMedGoogle Scholar
- Voisset C, Weiss RA, Griffiths DJ: Human RNA "rumor" viruses: the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev. 2008, 72 (1): 157-196. 10.1128/MMBR.00033-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Blomberg J, Ushameckis D, Jern P: Evolutionary aspects of human endogenous retroviral sequences (HERVs) and disease. Retroviruses and primate genome evolutionEurekah.com. Edited by: Sverdlov ED. 2005, 204-238.Google Scholar
- Garson J, Creange A, Dolei A, Ferrante P, Jouvin-Marche E, Marche PN, Rieger F, Ruprecht K, Saresella M, Sotgiu S, Tedder R, Perron H: MSRV, Syncytin and the role of endogenous retroviral proteins in demyelination. Mult Scler. 2005, 11 (2): 249-250. 10.1191/1352458505ms1160xx.View ArticlePubMedGoogle Scholar
- Dolei A, Perron H: The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease. J Neurovirol. 2009, 15 (1): 4-13. 10.1080/13550280802448451.View ArticlePubMedGoogle Scholar
- Laufer G, Mayer J, Mueller BF, Mueller-Lantzsch N, Ruprecht K: Analysis of transcribed human endogenous retrovirus W env loci clarifies the origin of multiple sclerosis-associated retrovirus env sequences. Retrovirology. 2009, 6: 37-10.1186/1742-4690-6-37.PubMed CentralView ArticlePubMedGoogle Scholar
- Flockerzi A, Maydt J, Frank O, Ruggieri A, Maldener E, Seifarth W, Medstrand P, Lengauer T, Meyerhans A, Leib-Mosch C, Meese E, Mayer J: Expression pattern analysis of transcribed HERV sequences is complicated by ex vivo recombination. Retrovirology. 2007, 4: 39-10.1186/1742-4690-4-39.PubMed CentralView ArticlePubMedGoogle Scholar
- Nellaker C, Yao Y, Jones-Brando L, Mallet F, Yolken RH, Karlsson H: Transactivation of elements in the human endogenous retrovirus W family by viral infection. Retrovirology. 2006, 3: 44-10.1186/1742-4690-3-44.PubMed CentralView ArticlePubMedGoogle Scholar
- Yao Y, Schroder J, Nellaker C, Bottmer C, Bachmann S, Yolken RH, Karlsson H: Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. Genes Brain Behav. 2007, 7 (1): 103-112.PubMedGoogle Scholar
- Bonnaud B, Bouton O, Oriol G, Cheynet V, Duret L, Mallet F: Evidence of selection on the domesticated ERVWE1 env retroviral element involved in placentation. Mol Biol Evol. 2004, 21 (10): 1895-1901. 10.1093/molbev/msh206.View ArticlePubMedGoogle Scholar
- Cheynet V, Ruggieri A, Oriol G, Blond JL, Boson B, Vachot L, Verrier B, Cosset FL, Mallet F: Synthesis, assembly, and processing of the Env ERVWE1/syncytin human endogenous retroviral envelope. J Virol. 2005, 79 (9): 5585-5593. 10.1128/JVI.79.9.5585-5593.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Voisset C, Blancher A, Perron H, Mandrand B, Mallet F, Paranhos-Baccala G: Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates. AIDS Res Hum Retroviruses. 1999, 15: 1529-1533. 10.1089/088922299309810.View ArticlePubMedGoogle Scholar
- Doms RW, Lamb RA, Rose JK, Helenius A: Folding and assembly of viral membrane proteins. Virology. 1993, 193 (2): 545-562. 10.1006/viro.1993.1164.View ArticlePubMedGoogle Scholar
- Ruggieri A, Maldener E, Sauter M, Mueller-Lantzsch N, Meese E, Fackler OT, Mayer J: Human endogenous retrovirus HERV-K(HML-2) encodes a stable signal peptide with biological properties distinct from Rec. Retrovirology. 2009, 6: 17-10.1186/1742-4690-6-17.PubMed CentralView ArticlePubMedGoogle Scholar
- An DS, Xie Y, Chen IS: Envelope gene of the human endogenous retrovirus HERV-W encodes a functional retrovirus envelope. J Virol. 2001, 75 (7): 3488-3489. 10.1128/JVI.75.7.3488-3489.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N: Endogenous retroviruses and cancer. Cell Mol Life Sci. 2008, 65: 3366-3382. 10.1007/s00018-008-8496-1.View ArticlePubMedGoogle Scholar
- Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG: A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 2002, 62 (19): 5510-5516.PubMedGoogle Scholar
- Mueller-Lantzsch N, Sauter M, Weiskircher A, Kramer K, Best B, Buck M, Grasser F: Human endogenous retroviral element K10 (HERV-K10) encodes a full-length gag homologous 73-kDa protein and a functional protease. AIDS Res Hum Retroviruses. 1993, 9 (4): 343-350. 10.1089/aid.1993.9.343.View ArticlePubMedGoogle Scholar
- Sauter M, Schommer S, Kremmer E, Remberger K, Dolken G, Lemm I, Buck M, Best B, Neumann-Haefelin D, Mueller-Lantzsch N: Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J Virol. 1995, 69 (1): 414-421.PubMed CentralPubMedGoogle Scholar
- Albert M, Antel J, Bruck W, Stadelmann C: Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 2007, 17 (2): 129-138. 10.1111/j.1750-3639.2006.00043.x.View ArticlePubMedGoogle Scholar
- Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D: The human genome browser at UCSC. Genome Res. 2002, 12 (6): 996-1006.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.